Kaposi sarcoma associated with rituximab-based cytotoxic therapy.

Ali Alkan Hatime Arzu YasarSerhat Toprak

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)

Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disease, mostly observed in immune compromised patients. KS is mostly encountered in HIV-positive or organ transplant patients. The drugs causing immunosuppression have also been associated with KS. Here, we present a KS experience associated with rituximab-based therapy.

Keyphrases

low grade
end stage renal disease
hiv positive
ejection fraction
newly diagnosed
chronic kidney disease
stem cells
bone marrow
antiretroviral therapy
human immunodeficiency virus